

- Journal of Current Microbiology and Applied Sciences, vol. 5(5), (2016), pp. 266-274.
- 5) S. E. Abd Elrazek, A. E. Bilasy, and A. E. Abd Elhalim, "Prior to the oral therapy, what do we know about HCV-4 in Egypt: a randomized survey of prevalence and risks using data mining computed analysis." *Medicine*, vol. 93(28), (2014).
 - 6) E. Hathorn and A. M. Elsharkawy, (2016) "Management of hepatitis C genotype 4 in the directly acting antivirals era." *BMJ Open Gastroenterology*, vol. 3(1), (2016), pp. e000112.
 - 7) B. Lam, B. L. Henry and Z. Younossi, "Sofosbuvir (Sovaldi) for the treatment of hepatitis C", *Expert Review of Clinical Pharmacology*, vol. 7(5), (2014), pp. 555-566.
 - 8) G. T. Everson, K. D. Sims, M. Rodriguez-Torres, C. Hézode, and D. F. Gardiner, "Efficacy of an interferon-and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naïve patients with HCV genotype 1 infection". *Gastroenterology*, vol. 146(2), (2014), pp. 420-429.
 - 9) H. K. Bhatia, H. Singh and N. Grewal, "Sofosbuvir: a novel treatment option for chronic hepatitis C infection." *Journal of Pharmacology and pharmacotherapy*, vol. 5, (2014), pp. 278-84.
 - 10) E. Lawitz, A. Mangia and D. Wyles, "Sofosbuvir for previously untreated chronic hepatitis C infection." *New England Journal of Medicine*, vol. 368, (2013) pp.1878-87.
 - 11) A. Elsharkawy, R. Fouad, and W. El Akel, "Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt." *Alimentary Pharmacological Therapy*, vol. 45, (2017), pp. 681-687.
 - 12) K. V. Kowdley, E. Lawitz and I. Crespo, "Sofosbuvir with pegylated interferon Alfa-2a and ribavirin for treatment-naïve patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial." *Lancet*, vol. 15, (2013) pp. 2100-2107
 - 13) H. Toyoda, T. Kumada and S. Kiriya, "Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response." *Liver International*, vol. 29, (2014), pp. 120-125.